J&J’s Yondelis Leads New Wave Of Sarcoma Drugs
This article was originally published in The Pink Sheet Daily
Labeling for second-line approval in rare soft tissue sarcomas cites progression-free survival benefit, with no significant survival improvement, in Phase III trial.
You may also be interested in...
Despite advisory committee discussion about a possible accelerated approval for pazopanib with a confirmatory study to assess symptom benefit, the agency opted to grant regular approval, as had been requested by GlaxoSmithKline.
Faced with the prospect of having to conduct another Phase III study, Johnson & Johnson opted to withdraw the trabectedin application and is reviewing the drug's clinical development program in recurrent ovarian cancer.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.